Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 3/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19384786 | 1.00 | HPGD (0.47) | HPGDHTTSMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL16580140 | 0.95 | PLK1 (0.43) | HPGDHTTSMN1; SMN2CYP3A4PLK1 | |
| SCHEMBL25133970 | 0.94 | PLK1 (0.46) | HPGDHTTSMN1; SMN2CYP3A4PLK1 | |
| SCHEMBL30269019 | 0.92 | PTGS1 (0.48) | HPGDHTTSMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL16133495 | 0.92 | HPGD (0.44) | HPGDHTTSMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL21632675 | 0.91 | AKT1 (0.44) | PLK1AKT1CA1CA2MGLL | |
| SCHEMBL28882673 | 0.89 | HTT (0.47) | HPGDHTTSMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL23760404 | 0.89 | SMN1; SMN2 (0.49) | HPGDHTTSMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL19678216 | 0.88 | PLK1 (0.44) | PLK1AKT1CA1CA2MGLL | |
| SCHEMBL22510595 | 0.88 | PLK1 (0.44) | PLK1AKT1CA1CA2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725560-A2 | ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | disclosed |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-27 | — | — | US | disclosed |
| US-12144865-B2 | Antibody drug conjugates with enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-11-19 | — | — | US | disclosed |
| EP-4406606-A2 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE G | Bayer Pharma Aktiengesellschaft (DE) | 2024-07-31 | — | — | EP | disclosed |
| US-20240043379-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-02-08 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-02-09 | — | — | US | disclosed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | disclosed |
| EP-3432934-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017162663-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | HPGD 1790/4885HTT 4356/4885SMN1; SMN2 1282/4885 |
| US-20240043379-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BUB1B, KIF5B, TK1 | HPGD 1790/4885HTT 4356/4885SMN1; SMN2 1282/4885 |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | KIF18B, KIF18A, KIF5B | HPGD 3252/4885HTT 2667/4885SMN1; SMN2 1367/4885 |
| US-12144865-B2 | Antibody drug conjugates with enzymatically cleavable groups | KIFC1, KIF2C, KIF5B | HPGD 4181/4885HTT 2841/4885SMN1; SMN2 1430/4885 |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | KIFC1, KIF2C, KIF5B | HPGD 4090/4885HTT 2881/4885SMN1; SMN2 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.